CheckMate 016
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
- NCT01472081 ↗
- Completed
- Bristol-Myers Squibb
- Focused
We haven't built an HCP commentary report on CheckMate 016 (nivolumab plus ipilimumab; nivolumab plus sunitinib; nivolumab plus pazopanib in clear-cell metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CheckMate 016 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- Nivolumab; Pazopanib; Sunitinib; Ipilimumab
- Arms
- Arm S: Nivolumab + Sunitinib · Experimental
- Arm P: Nivolumab + Pazopanib · Experimental
- Arm I-1: Nivolumab + Ipilimumab · Experimental
- Arm I-3: Nivolumab + Ipilimumab · Experimental
- Arm IN-3: Nivolumab+Ipilimumab · Experimental
- Enrollment
- 194
- Primary outcomes
- Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Feb 9, 2012
- Primary completion
- Feb 2, 2016
- Results posted
- Yes
- Registry record
- NCT01472081 · updated Dec 2, 2021
Publications
linked from the registry- Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. PubMed 30348216
- Dorff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. doi: 10.1586/17512433.2014.862496. Epub 2013 Dec 2. PubMed 24308791